to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
TTY Biopharm will become a co-development partner of to-BBB for the manufacturing of brain-targeted doxorubicin liposomes. These liposomes are essential for the clinical development of to-BBB’s lead product for the treatment of brain cancer.
Werner Gladdines, Head of Clinical Operations at to-BBB, is very pleased with this agreement: “TTY Biopharm is highly specialized in the preparation of doxorubicin PEG-liposomes and will thus be able to efficiently manufacture brain-targeted doxorubicin liposomes with the same precision within a short timeframe. Working with TTY Biopharm, therefore, greatly accelerates our clinical development of our lead product for brain cancer”.
Based on its proprietary G-Technology, discovered by the Industrial Technology Research Institute (ITRI) in Taiwan, to-BBB is developing its lead compound, brain-targeted doxorubicin liposomes. These liposomes are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. Doxorubicin glutathione-PEG liposomes have shown a reduced brain tumor growth in proof-of-concept studies, which provides a strong basis for clinical development. For this development, to-BBB requires clinical scale batches of the brain-targeted doxorubicin liposomes, produced according to cGMP standards. TTY Biopharm will provide these liposomes in a timely manner.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services - New agreements signed with Boehringer Ingelheim Germany and Canada
MBL scientists find genes linked to human neurological disorders in sea lamprey genome - Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury
Merck Proposes the Creation of a Global Alliance for the Elimination of Schistosomiasis
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
